Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1637 1654
This examiner grants 52% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17854589 | Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17272190 | TARGETING KIT WITH SPLICE SWITCHING OLIGONUCLEOTIDES TO INDUCE APOPTOSIS OF MAST CELLS | Final Rejection | North Carolina State University |
| 17401114 | RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION | Final Rejection | AMGEN INC. |
| 16611548 | CONJUGATION OF PEPTIDES TO SPHERICAL NUCLEIC ACIDS (SNAS) USING TRACELESS LINKERS | Non-Final OA | Northwestern University |
| 17281049 | METHODS FOR PREVENTING AND TREATING PULMONARY INFLAMMATION AND FIBROSIS | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 17078627 | METHODS FOR TREATING PARKINSON'S DISEASE | Final Rejection | Korea Advanced Institute of Science and Technology |
| 17846636 | NOVEL RNA THERAPEUTICS AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 17047967 | MITOCHONDRIAL RNA IMPORT FOR TREATING MITOCHONDRIAL DISEASE | Non-Final OA | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17704915 | OLIGONUCLEOTIDES FOR SYNGR-3 MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17391475 | OLIGONUCLEOTIDES FOR HTT-1A MODULATION | Non-Final OA | UNIVERSITY OF MASSACHUSETTS |
| 17235153 | OLIGONUCLEOTIDES FOR MSH3 MODULATION | Final Rejection | UNIVERSITY OF MASSACHUSETTS |
| 18581511 | BETA-CATENIN (CTNNB1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17773508 | COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 17451521 | MICRO RNA INTERACTIONS AS THERAPEUTIC TARGETS FOR COVID-19 AND OTHER VIRAL INFECTIONS | Non-Final OA | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT |
| 18612850 | COMPOSITIONS AND METHODS FOR ENHANCED ANTIGEN BINDING PROTEINS | Non-Final OA | HDT Bio Corp. |
| 18443619 | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18150395 | ANTISENSE COMPOUNDS | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 16951449 | Compounds and Methods for Modulation of Transcript Processing | Final Rejection | Ionis Pharmaceuticals, Inc. |
| 16474198 | SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO | Final Rejection | Editas Medicine, Inc. |
| 18285904 | Oligonucleotides | Non-Final OA | Hudson Institute of Medical Research |
| 17264790 | OLIGONUCLEOTIDES COMPRISING A PHOSPHOROTRITHIOATE INTERNUCLEOSIDE LINKAGE | Final Rejection | Roche Innovation Center Copenhagen A/S |
| 18250629 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROMUSCULAR DISEASES COMPRISING CDO PROTEIN OR GENE ENCODING SAME | Non-Final OA | ANIMUSCURE INC. |
| 17920065 | Compositions and Methods Using SNRNA Components | Non-Final OA | Shape Therapeutics Inc. |
| 17882009 | MICRORNA COMPOSITIONS AND METHODS OF USE | Non-Final OA | New York R&D Center for Translational Medicine and Therapeutics, Inc. |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | Non-Final OA | CureVac AG |
| 17415155 | SYNTHETIC MICRORNA MIMICS | Non-Final OA | RNATIVES INC. |
| 17265386 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASES | Non-Final OA | LEMONEX INC. |
| 17055061 | SUBSTITUTION OF THE MESSENGER RNA CAP WITH TWO RNA SEQUENCES INTRODUCED AT THE 5-PRIME END THEREOF | Non-Final OA | MESSENGER BIOPHARMA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy